Skip to main content
. 2014 Sep 15;9:975–981. doi: 10.2147/COPD.S63568

Table 2.

Patients followed up (n=94)

Weight loss >5%
(n=15)
Minimal weight loss/gain <5%
(n=62)
Weight gain >5%
(n=17)
P-value
Weight change over study, kg* −6.1 (0.6) −0.2 (0.3) 5.3 (0.6) <0.01
Weight change over study, %* −8.9 (0.8) −0.2 (0.4) 7.8 (0.8) <0.01
Male, n (%) 9 (60%) 46 (74%) 10 (59%) 0.34
Age, years 66 (43 to 85) 69 (48 to 84) 66 (46 to 77) 0.23
Pack-year history 35 (21 to 51) 40 (26 to 51) 47 (37 to 59) 0.32
Δ exacerbation frequency between baseline and follow-up* −0.5 (−2.4 to 1.4) −0.9 (−1.6 to 0.2) −2.0 (−3.8 to −0.3) 0.29
Δ FEV1 (L)* −0.07 (−0.19 to 0.05) −0.15 (−0.22 to −0.09) −0.02 (−0.18 to 0.13) 0.15
Δ FEV1 (% predicted)* −3 (−8 to 2) −5 (−8 to −3) 0 (−6 to 6) 0.13
Δ DLCO (% predicted)* −2 (−7 to 2) 0 (−2 to 3) 9 (2 to 17) <0.01
Δ RV (% predicted)* 8 (−11 to 28) 7 (−2 to 17) −4 (−21 to 14) 0.50
Δ blood white cell count, ×109/L* 0.6 (−0.3 to 1.5) 0.0 (−0.5 to 0.5) −1.2 (−2.5 to 0.2) 0.04
Δ blood neutrophils, ×109/L* 0.6 (−0.3 to 1.5) 0.1 (−0.4 to 0.7) −1.0 (−2.1 to 0.2) 0.06
Δ blood eosinophils, ×109/L* −0.03 (−0.09 to 0.03) 0.00 (−0.04 to 0.05) 0.01 (−0.10 to 0.12) 0.79
Δ CRP, mg/L* −5 (−11 to 1) 0 (−4 to 3) 3 (−4 to 3) 0.34
Δ sputum total cell count, ×106 cells/g* −3.5 (−8.8 to 1.9) 0.1 (−3.5 to 3.7) 1.3 (−5.0 to 7.6) 0.58
Δ sputum neutrophils (%)* 10.6 (−3.5 to 24.7) −2.7 (−12.3 to 6.9) 11.9 (1.6 to 22.2) 0.15
Δ sputum eosinophils (%)* −4.4 (−13.0 to 4.1) 0.4 (−0.7 to 1.5) −5.4 (−11.1 to 0.4) 0.02

Notes: Data expressed as mean (SEM) unless otherwise stated.

*

Mean (95% CI);

mean (range);

median (interquartile range).

Abbreviations: Δ, change between baseline and follow-up measure; CI, confidence interval; CRP, C reactive protein; DLCO, total lung carbon monoxide diffusing capacity; FEV1, forced expiratory volume in 1 second; RV, residual volume; SEM, standard error of the mean.